Bazedoxifene — drug · CancerIndex

Regulatory

Approvals (0)

Each record names the authority, jurisdiction, indication text and status. A drug approved in one jurisdiction for one indication is not 'approved' in general.

Data not yet available

No regulatory approval recorded. Absence here is not evidence of absence: only ingested jurisdictions are covered.

What CancerIndex knows

Curated evidence below
Sources

Derived

Development pipeline

Most advanced stage across all cancers, then per top-level cancer reached through trial conditions or approval indications. Approval in any ingested jurisdiction outranks trial phase; counts are interventional studies.

Scope	Stage	Max phase	Trials	Jurisdictions	First approval	First trial
All cancers	Phase2	Phase 2	2	—	—	Jul 9, 2015
Malignant Breast Neoplasm	Phase2	Phase 2	1	—	—	Jul 9, 2015
Malignant Pancreatic Neoplasm	Phase Not Stated	N/A	1	—	—	Feb 1, 2022

Computedclinicaltrials

Curated evidence

Clinical evidence (2)

CIViC items in which this therapy appears, grouped by cancer context, then molecular profile. 50 items per page.

civicCuratedShowing 1–2 of 2 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
PIK3CA Mutation1
Bazedoxifene + Palbociclib Regimen

Clinical trials

Trials with this intervention (2)

Most recently updated first, 50 per page.

clinicaltrialsPublishedShowing 1–2 of 2 studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT02448771	A Study of Palbociclib in Combination With Bazedoxifene in Hormone Receptor Positive Breast Cancer	completed	Phase 1 / Phase 2	36	Dana-Farber Cancer InstituteOTHER	1	Oct 24, 2022	clinicaltrials
NCT04812808	Bazedoxifene as a Concomitant Treatment of Patients With Metastatic Pancreatic Adenocarcinoma(BAZE)	unknown